When compared with bevacizumab, BI 836880 appeared to show at least comparable activity as bevacizumab in terms of its anti-proliferative and anti-angiogenic effects. This study showed that BI 836880 has anti-proliferative, anti-angiogenic and possibly immunomodulatory effect in clinical models of NPC, therefore the dual targeting of VEGF and Ang2 signaling in NPC should be further investigated.
MTD was not reached. BI 836880 alone and in combination with ezabenlimab had a manageable safety profile with preliminary clinical activity in Japanese patients with advanced solid tumors.
over 1 year ago
P1 data • Clinical Trial,Phase I • Journal • Metastases
Angiogenesis marker CD34 was analyzed by IHC staining and the microvessel densities were calculated by Image J. The results showed that BI836880 could significantly reduce the numbers of microvessels to a comparable extent as bevacizumab in NPC model. In addition, BI836880 had increased the tumor internal necrotic area by 118.7% compared to vehicle control in Xeno-2117 (p=0.0148), but the effect was insignificant in Xeno-666 (p=0.5467).In conclusion, BI836880 can inhibit NPC growth to an extent that is comparable to bevacizumab, further investigation in combination with cytotoxic or immunotherapeutic agents are warranted.
over 3 years ago
Preclinical • IO biomarker
|
VEGFA (Vascular endothelial growth factor A) • CD34 (CD34 molecule)
This data indicates a brain-specific group effect of antiangiogenic compounds with respect to metastasis prevention, most likely by preventing an early angiogenic switch. Thus, Nintedanib and BI836880 are promising candidates for future BM preventive study concepts in lung adenocarcinoma patients.
In Part 2 (expansion phase), patients are recruited to one of 7 cohorts: mNSCLC after CPI monotherapy; mNSCLC after CT + CPI; mSCLC after CT ± CPI; immunotherapy-resistant m-melanoma; recurrent glioblastoma after 1st-line CT; HCC after prior sorafenib or lenvatinib; and previously untreated/unresectable HCC. Funding: Boehringer Ingelheim. Clinical trial identification: NCT03468426.
over 4 years ago
Clinical • P1 data • Combination therapy
|
VEGFA (Vascular endothelial growth factor A) • ANGPT2 (Angiopoietin 2)
|
sorafenib • Lenvima (lenvatinib) • ezabenlimab (BI 754091) • BI 836880
Part 2 will assess safety and efficacy in 6 expansion cohorts: mNSCLC after CPI monotherapy; mNSCLC after CT + CPI; mSCLC after CT ± CPI; immunotherapy-resistant m-melanoma; recurrent glioblastoma after 1st-line CT; and hepatocellular carcinoma after prior sorafenib or lenvatinib ± subsequent CPI. MTD/RP2D was BI 836880 720 mg plus BI 754091 240 mg q3w. The combination had a manageable safety profile, and preliminary anti-tumor activity was observed. Expansion cohorts are ongoing.
over 4 years ago
Clinical • P1 data • Combination therapy
|
VEGFA (Vascular endothelial growth factor A) • ANGPT2 (Angiopoietin 2)
|
sorafenib • Lenvima (lenvatinib) • ezabenlimab (BI 754091) • BI 836880